Science in Action has confirmed that it has received ethics approval for an in vivo non-GLP toxicology study of N, N Dimethyltryptamine (DMT) (the "Study"). Both Entheon and Science in Action have applied for requisite permits in order to export, receive and research DMT drug product.
A 2018 study provides further clarity on the relationship between psychedelics and schizophrenia. Both break down the barriers between self and other. We know LSD does this by quieting parts of the brain related to ego we’re back to the influence on the 5-HT2A receptors again. (We’re unclear why this occurs in schizophrenics.)
Columbia University Professor Snorts Heroin to Maintain ‘Work-Life Balance’, Claims It’s Not Addictive
Columbia University Professor Snorts Heroin to Maintain 'Work-Life Balance', [...]
Silverstone said where psychedelics are legal, private clinics are beginning to offer them but charge several thousand dollars. His clinic and online resource would make psychedelics more accessible.
Currently, Health Canada grants exemptions that allow for individual therapy sessions using psilocybin for the terminally ill. The new clinic will start with this mandate, but Harder hopes to see it expand.
The situation has prompted lawmakers to consider a measure that would remove psilocybin from the list of Schedule 1 substances, which includes heroin, LSD and ecstasy.
Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
MindMed has several therapies based on lysergic acid diethylamide (LSD) in the phase 2 for treatment of anxiety and cluster headaches, which would be used as an aid during therapy sessions.
Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial functioning improved across the cohort.